Tirzepatide Proves More Effective Than Semaglutide – Results of Surmount 5 Trial
SURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of tirzepatide 15 mg or MTD (10 mg or 15 mg) compared with semaglutide 2.4 mg or MTD (1.7 mg or 2.4 mg) in adults with obesity or overweight with at least one obesity-related complication, excluding diabetes. All […]